Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Moderna Inc MRNA

Healthcare Biotechnology
Moderna, Inc. is a biotechnology company. The Company is advancing a new class of medicines made of messenger ribonucleic acid (mRNA). It is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases, independently and with its strategic collaborators. mRNA medicines are designed to direct the body’s cells to produce intracellular... see more

Recent & Breaking News (NDAQ:MRNA)

Moderna Receives FDA Authorization for Emergency Use of Its COVID-19 Vaccine for Children 6 Months of Age and Older

Accesswire June 17, 2022

Moderna Announces Omicron-Containing Bivalent Booster Candidate mRNA-1273.214 Demonstrates Superior Antibody Response Against Omicron

Accesswire June 8, 2022

Moderna Announces First Participants Dosed in Phase 3 Study of Seasonal Influenza Vaccine Candidate (mRNA-1010)

Accesswire June 7, 2022

Moderna and the European Commission Agree on Amendment to COVID-19 Vaccine Supply Agreement

Accesswire June 2, 2022

Moderna to Present at Upcoming Conferences in June 2022

Accesswire June 1, 2022

Takeda and Moderna Announce Plans to Transfer Marketing Authorization for Spikevax(TM) COVID-19 Vaccine in Japan to Moderna

Business Wire May 31, 2022

Moderna and Takeda Announce Plans to Transfer Marketing Authorization for Spikevax(TM) COVID-19 Vaccine in Japan to Moderna

Accesswire May 31, 2022

Senti Bio Secures Additional Financing from Leaps by Bayer and Provides Update on Proposed Business Combination with Dynamics Special Purpose Corp. (DYNS)

GlobeNewswire May 24, 2022

Moderna to Present at the UBS 2022 Global Healthcare Conference

Accesswire May 18, 2022

IAVI and Moderna Launch First-in-Africa Clinical Trial of mRNA HIV Vaccine Development Program

Accesswire May 18, 2022

Moderna Announces Advancements in mRNA Platform Science for Application Across Multiple Diseases at Science and Technology Day

Accesswire May 17, 2022

Departure of Jorge Gomez and Continuation of David Meline as Chief Financial Officer

Accesswire May 11, 2022

Moderna to Host Annual Science and Technology Day on May 17, 2022

Accesswire May 9, 2022

Moderna Reports First Quarter 2022 Financial Results and Provides Business Updates

Accesswire May 4, 2022

Moderna to Build Vaccine Facility in Quebec

Stockhouse Editorial May 2, 2022

Moderna Files to Expand Conditional Marketing Authorization for Its COVID-19 Vaccine to Include Children Six Months to Under Six Years in The European Union

Accesswire April 29, 2022

Moderna Finalizes Plan for Long-Term Strategic Partnership with The Government of Canada

Accesswire April 29, 2022

Moderna Files for Authorization of Its COVID-19 Vaccine in Young Children Six Months to Under Six Years of Age

Accesswire April 28, 2022

Arpa Garay Joins Moderna as Chief Commercial Officer

Accesswire April 27, 2022

Moderna Announces Clinical Update on Bivalent COVID-19 Booster Platform

Accesswire April 19, 2022